Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA synthesis inhibition refers to the process of blocking the production of RNA molecules from DNA or RNA templates, a critical step in gene expression and viral replication. The primary molecular target for this inhibition is typically the enzyme RNA polymerase, which catalyzes the transcription of DNA into messenger RNA (mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA). In viruses with an RNA genome, an RNA-dependent RNA polymerase (RdRp) is responsible for replicating viral genetic material. Inhibitors of bacterial RNAP are crucial antibiotics used against tuberculosis (Mycobacterium tuberculosis) and other Gram-positive/negative infections. Viral RdRp inhibitors form part of antiviral regimens against diseases like hepatitis C.
Blocks initiation or elongation during transcription by binding to RNA polymerase or chelating essential divalent cations.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA Synthesis Inhibition.